- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02800590
Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy (ABP-700)
February 19, 2018 updated by: The Medicines Company
A Phase II, Two-part, Multiple-dose, Dose-finding, Single-blind Study to Investigate the Safety and Efficacy of ABP-700 for Procedural Sedation in Adult Patients Undergoing Colonoscopy
This is a phase II, two-part, multiple-dose, dose-finding, single-blind study in adult participants undergoing elective colonoscopy for screening or diagnostic purposes.
This study is designed to test various ABP-700 infusion regimens for rational selection of one or more dosage regimen(s) to be used for future clinical development of ABP-700 in procedural sedation.
Study Overview
Detailed Description
In Part 1, three ABP-700 two-stage infusion regimens will be evaluated.
A sample size of 75 evaluable participants will be randomly assigned to dose regimens in a 1:1:1 ratio.
Following the completion of Part 1, a Data Review Committee (DRC) will review the dose-response, efficacy, and safety data and provide recommendations on whether to continue the study to Part 2 and the number of ABP-700 infusion regimens to be included in Part 2. The Sponsor (MDCO) will make the final decision to proceed with Part 2 (whether to conduct Part 2 and number of dose regimens if the study continues to Part 2) based on the recommendation from the DRC.
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Groningen, Netherlands
- Martini Hospital
-
Groningen, Netherlands
- University Medical Center Groningen (UMCG)
-
Nijmegen, Netherlands
- Radboud University Nijmegen Medical Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant must be male or female 18 to 75 years of age, inclusive
- Participant must give written informed consent before initiation of any study-related procedures
- Participant is scheduled to undergo elective colonoscopy
- Body Mass Index (BMI) 18.0 to 29.0 kilogram per meter squared (kg/m^2)
- American Society of Anesthesiology (ASA) class I to II
- Modified Mallampati score I to II
- If female and of child-bearing potential, participant must have a negative pregnancy test during screening and cannot be breast-feeding
- If participant is a sexually active male or a sexually active female of child-bearing potential, he or she must agree to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
Exclusion Criteria:
- Any ASA physical status III or worse, or history of one or more of the following: history or presence of significant cardiovascular disease, including atrial fibrillation or cardiovascular disease risk factors, hyperlipidemia, coronary artery disease, or any known genetic pre disposition to cardiac arrhythmia (including long QT syndrome, > 450 milliseconds [msec]); history of any neurological or seizure disorder or psychiatric disease; history or presence of significant pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic or dermatologic disease; history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the participant by their participation in the study.
- History of any recent illness (such as, upper respiratory infection) that does not satisfy ASA III or greater requirements but in the opinion of the investigator, may pose an additional risk to the participant by their participation in the study.
- Participants with a history of essential hypertension that are not well controlled on medication will be accepted. Participants should have been diagnosed with hypertension for at least 6 months and/or are not on stable therapy for at least 4 weeks prior to the study.
- Surgery within the past 90 days prior to dosing judged by the investigator to be clinically relevant.
- History of febrile illness within 5 days prior to dosing.
- Participants in whom airway management is judged to be potentially difficult; thyromental distance ≤ 4 centimeters (cm) or Mallampati scores of 3 or 4 or per the discretion of the anesthesiologist based on history and physical exam.
- History or presence of alcoholism, drug abuse, or illicit drug use within the past 2 years.
- Hypersensitivity or idiosyncratic reaction to components of ABP-700 (sulfobutylether-beta-cyclodextrin, citrate buffer, sodium hydroxide), remifentanil or midazolam.
- Participant is the investigator or his/her deputy, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study.
- Participation in another interventional clinical trial within 90 days prior to dosing. The 90-day window will be derived from the date of the last study procedure (such as last blood collection or dosing) in the previous study to Day 1 of the current study.
- Participants who, for any reason, are deemed by the investigator to be inappropriate for this study, including participants who are unable to communicate or to cooperate with the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ABP-700 30 μg/kg/min
Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete.
Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
|
|
EXPERIMENTAL: ABP-700 40 μg/kg/min
Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete.
Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
|
|
EXPERIMENTAL: ABP-700 45 μg/kg/min
Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete.
Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Successfully Completed Procedures by Assigned ABP-700 Infusion Dose
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Successfully Completed Procedures by Assigned ABP-700 Infusion Dose with and without Supplemental Bolus ABP-700
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Number of Successfully Completed Procedures by Assigned ABP-700 Infusion Dose with and without Supplemental Bolus ABP-700 that Require or Do Not Require Rescue Sedative Medication
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Time to Procedure Start
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Depth and Duration of Sedation
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Number of Supplemental ABP-700 Bolus Doses Required
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Recovery from Sedation and Discharge Conditions as Assessed by the Modified Aldrete Score (APRS)
Time Frame: Treatment period (Day 1)
|
Treatment period (Day 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: A.R. Absalom, MD, University Medical Center Groningen (UMCG)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2016
Primary Completion (ACTUAL)
June 1, 2017
Study Completion (ACTUAL)
June 1, 2017
Study Registration Dates
First Submitted
June 10, 2016
First Submitted That Met QC Criteria
June 14, 2016
First Posted (ESTIMATE)
June 15, 2016
Study Record Updates
Last Update Posted (ACTUAL)
February 20, 2018
Last Update Submitted That Met QC Criteria
February 19, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDCO-ABP-15-01
- 2015-004019-19 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colonoscopy
-
Borland-Groover ClinicValley Medical Products, LLC is paying for the study and is the sponsor....CompletedColonoscopy | Screening Colonoscopy | Surveillance ColonoscopyUnited States
-
Josue AliagaCompleted
-
Endostart srlCompleted
-
Rambam Health Care CampusUnknownInadequate Preparation for Colonoscopy; Personalized Colonoscopy PreparationIsrael
-
Hospital Central Norte PEMEXRecruitingPerformance of Colonoscopy | Tolerance of ColonoscopyMexico
-
VA Office of Research and DevelopmentVA Palo Alto Health Care System; VA Northern California Health Care SystemCompletedWater Exchange Colonoscopy | Unsedated Colonoscopy | Cap | Colonoscopy PainUnited States
-
Dalin Tzu Chi General HospitalCompletedColonoscopy | Intubation Time | Cap-assisted ColonoscopyTaiwan
-
Valduce HospitalCompletedUnsedated Colonoscopy | Warm Water | CO2 ColonoscopyItaly
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...UnknownColonoscopy | Complete Colonoscopy | Cecum Intubation Time | İleum Intubation TimeTurkey
-
Daewoong Pharmaceutical Co. LTD.Not yet recruiting
Clinical Trials on ABP-700
-
AcusphereCompletedCoronary Artery DiseaseUnited States
-
Carolina Eyecare Physicians, LLCScience in VisionRecruiting
-
Anokion SAActive, not recruitingRelapsing Remitting Multiple Sclerosis | Multiple Sclerosis (MS)United States
-
Toray Industries, IncCompletedPost-Herpetic NeuralgiaJapan
-
Prim. Prof. Dr. Oliver Findl, MBACompleted
-
OFTALVIST (Oftalmología Vistahermosa S.L)Completed
-
Millennium Pharmaceuticals, Inc.Completed
-
AcusphereCompletedChronic Obstructive Pulmonary Disease | Congestive Heart FailureUnited States
-
Advanced Vision CareClinical Research Consultants, Inc.Recruiting
-
Multack Eye CareCompleted